Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: A prospective study

Cancer Research

Volumn 71, Issue 10, 2011, Pages 3582-3589

  Jiao, Li ^a   Weinstein, Stephanie J ^a   Albanes, Demetrius ^a   Taylor, Philip R ^a   Graubard, Barry I ^a   Virtamo, Jarmo ^b   Stolzenberg Solomon, Rachael Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; FINNISH; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DOUBLE-BLIND METHOD; FINLAND; GLUCOSE; HUMANS; INSULIN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PANCREATIC NEOPLASMS; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; RISK; SMOKING;

EID: 79956159720     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2573     Document Type: Article

References (47)

1. Anderson KA, Mack T, Silverman DT. Pancreatic cancer. In: Schottenfeld D, Fraumeni J, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2006. p. 741-2.
2. Thiébaut AC, Jiao L, Silverman DT, Cross AJ, Thompson FE, Subar AF, et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst 2009;14:1001-11.
3. Stolzenberg-Solomon RZ, Cross AJ, Silverman DT, Schairer C, Thompson FE, Kipnis V, et al. Meat and meat-mutagen intake and pancreatic cancer risk in the NIH-AARP cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2664-75. (Pubitemid 351196322)
4. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003;33:3-14.
5. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-8. (Pubitemid 41785868)
6. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005;15:16R-28R.
7. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm 2008;14:987-9. (Pubitemid 351753287)
8. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46. (Pubitemid 32156196)
9. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-6.
10. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, et al. Tobacco smoke is a source of toxic reactive glycation products. Pro Nat Acad Sci U S A 1997;94:13915-20. (Pubitemid 28009684)
11. Dickerson TJ, Janda KD. A previously undescribed chemical link between smoking and metabolic disease. Proc Natl Acad Sci U S A 2002;99:15084-8. (Pubitemid 35334613)
12. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005;1043:452-60. (Pubitemid 41123933)
13. Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: a general overview. Hormones (Athens) 2005;4:28-37.
14. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Thorpe SR. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 1996;11 Suppl 5:48-53. (Pubitemid 27062911)
15. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996;45 Suppl 3:S77-80.
16. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009;87:235-47.
17. Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal 2009;7:12.
18. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009;5:389-401.
19. Bachmeier BE, Nerlich AG, Rohrbach H, Schleicher ED, Friess U. Maillard products as biomarkers in cancer. Ann N Y Acad Sci 2008;1126:283-7. (Pubitemid 351589319)
20. Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205:275-85. (Pubitemid 351281593)
21. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007;7:777-89.
22. Sparvero LJ, safu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:17.
23. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 2007;25:720-5. (Pubitemid 350223177)
24. Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 2010;57:55-61.
25. Krechler T, Jachymova M, Mestek O, Zak A, Zima T, Kalousova M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 2010;43:882-6.
26. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994;4:1-10.
27. Kulathinal S, Karvanen J, Saarela O, Kuulasmaa K. Case-cohort design in practice - experiences from the MORGAM Project. Epidemiol Perspect Innov 2007;4:15.
28. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002;41:381-8.
29. Pietinen P, Hartman AM, Haapa E, Räsänen L, Haapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol 1988;128:655-66.
30. Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, et al. Elevated serum levels of N(epsilon)-carboxymethyllysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004;47:1376-9. (Pubitemid 39232422)
31. Hu FB, Stampfer MJ, Rimm E, Ascherio A, Rosner BA, Spiegelman D, et al. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol 1999;149:531-40. (Pubitemid 29130020)
32. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009;11:2251-63.
33. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation end-products-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996;222:700-5. (Pubitemid 26194815)
34. Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001;48:1577-8. (Pubitemid 34003479)
35. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
36. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006;11:646-54.
37. Ouslimani N, Mahrouf M, Peynet J, Bonnefont-Rousselot D, Cosson C, Legrand A, et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor. Metabolism 2007;56:308-13. (Pubitemid 46209221)
38. Michaud DS, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst 2007;99:171-5.
39. Stolzenberg-Solomon RZ, Dodd KW, Blaser MJ, Virtamo J, Taylor PR, Albanes D . Tooth loss, pancreatic cancer, and Helicobacter pylori. Am J Clin Nutr 2003;78:176-81. (Pubitemid 39655263)
40. Katz J, Caudle RM, Bhattacharyya I, Stewart CM, Cohen DM. Receptor for advanced glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine. J Periodontol 2005;76:1171-4. (Pubitemid 41065408)
41. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13:185-9. (Pubitemid 46944961)
42. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756-62.
43. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-34. (Pubitemid 44833448)
44. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634-46.
45. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and nondiabetic subjects. Clin Exp Med 2007;7:188-90.
46. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227-31. (Pubitemid 44215942)
47. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 2004;63:449-52. (Pubitemid 38993609)